These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33209499)

  • 41. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer.
    Gao SJ; Corso CD; Wang EH; Blasberg JD; Detterbeck FC; Boffa DJ; Decker RH; Kim AW
    J Thorac Oncol; 2017 Feb; 12(2):314-322. PubMed ID: 27720827
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal surgical timing and radiotherapy dose for trimodality therapy in locally advanced non-small cell lung cancer.
    Han JE; Hasan S; Choi JI; Press RH; Simone CB
    Cancer Med; 2021 Sep; 10(17):5794-5808. PubMed ID: 34350713
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis.
    Miccio JA; Talcott WJ; Patel T; Park HS; Cecchini M; Salem RR; Khan SA; Stein S; Kortmansky JS; Lacy J; Narang A; Herman J; Jabbour SK; Hallemeier CL; Johung K; Jethwa KR
    Clin Transl Radiat Oncol; 2021 Mar; 27():15-23. PubMed ID: 33392398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer.
    Lutfi W; Talamonti MS; Kantor O; Wang CH; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
    Am J Surg; 2017 Mar; 213(3):521-525. PubMed ID: 28089341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survival outcomes of neoadjuvant and adjuvant chemoradiotherapy for locally advanced adenocarcinoma of the oesophagogastric junction: a retrospective cohort study using the SEER database.
    Zhang F; Feng X; Li Y; Yan J; Zhang Z; Song X
    J Gastrointest Oncol; 2022 Feb; 13(1):26-39. PubMed ID: 35284136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 47. The impact of chemotherapy sequencing on resectable pancreatic cancer by stage.
    Vega EA; Kutlu OC; Salehi O; Alarcon SV; Abudalou M; Kozyreva O; Krishnan S; Lee D; Freeman R; Conrad C
    Surg Oncol; 2022 Mar; 40():101694. PubMed ID: 34973593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meta-Analysis for the Therapeutic Effect of Neoadjuvant Therapy in Resectable Esophageal Cancer.
    Zhu Y; Liu M; Yun X; Wang D; Bai Y; Zhang G; Ji B; Jing C
    Pathol Oncol Res; 2017 Jul; 23(3):657-663. PubMed ID: 28013492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retrospective review of total neoadjuvant therapy.
    Babar L; Bakalov V; Abel S; Ashraf O; Finley GG; Raj MS; Lundeen K; Monga DK; Kirichenko AV; Wegner RE
    World J Gastrointest Oncol; 2019 Oct; 11(10):857-865. PubMed ID: 31662824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survival after Margin-Positive Resection in the Era of Modern Chemotherapy for Pancreatic Cancer: Do Patients Still Benefit?
    Arrington AK; Hsu CH; Schaefer KL; O'Grady CL; Khreiss M; Riall TS
    J Am Coll Surg; 2021 Jul; 233(1):100-109. PubMed ID: 33781861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel Calculator to Estimate Overall Survival Benefit from Neoadjuvant Chemoradiation in Patients with Esophageal Adenocarcinoma.
    Gabriel E; Attwood K; Shah R; Nurkin S; Hochwald S; Kukar M
    J Am Coll Surg; 2017 May; 224(5):884-894.e1. PubMed ID: 28147252
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
    Front Oncol; 2020; 10():41. PubMed ID: 32083002
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
    Jiang DM; Raissouni S; Mercer J; Kumar A; Goodwin R; Heng DY; Tang PA; Doll C; MacLean A; Powell E; Price-Hiller J; Monzon J; Cheung WY; Vickers MM
    Ann Oncol; 2015 Oct; 26(10):2102-6. PubMed ID: 26232491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimal timing and treatment strategy for pancreatic cancer.
    Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
    J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of neoadjuvant chemotherapy and chemoradiotherapy on postoperative cardiopulmonary complications in patients with esophageal cancer.
    Zhang Z; Zhang H
    Dis Esophagus; 2017 Apr; 30(4):1-7. PubMed ID: 28375486
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.
    Jiang W; Haque W; Verma V; Butler EB; Teh BS
    Acta Oncol; 2019 Sep; 58(9):1259-1266. PubMed ID: 31237185
    [No Abstract]   [Full Text] [Related]  

  • 57. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
    van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
    Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
    Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
    J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis.
    Jing SW; Qin JJ; Liu Q; Zhai C; Wu YJ; Cheng YJ; Czito BG; Wang J
    Future Oncol; 2019 Jul; 15(20):2413-2422. PubMed ID: 31269806
    [No Abstract]   [Full Text] [Related]  

  • 60. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Zou Y; Gao S; Yu X; Zhou T; Xie Y; Guo X; An R; Wang X; Zhao T; Chang A; Gao C; Yu J; Hao J
    Int J Surg; 2023 Jun; 109(6):1573-1583. PubMed ID: 37132194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.